ALPPL2 Is a Highly Specific and Targetable Tumor Cell Surface Antigen
Authors:
Open Access
- 31 August 2020
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 80 (20) , 4552-4564
Abstract
Identification of tumor-specific cell surface antigens has proven challenging, as the vast majority of tumor-associated antigens are also expressed in normal tissues. In mesothelioma, we identified a highly specific tumor cell surface antigen that can be targeted for therapy development. Mesothelioma is caused by malignant transformation of the mesothelium, is incurable, and can be categorized into three histologic subtypes: epithelioid, biphasic, and sarcomatoid. To identity novel mesothelioma cell surface antigens with broad subtype coverage and high tissue specificity, we have previously selected phage antibody display libraries on live mesothelioma cells and tissues following counterselection on normal cells and identified a panel of human antibodies that bind all subtypes of mesothelioma, but not normal mesothelium. One of the antibodies, M25, showed high specificity against an antigen we identify here as ALPPL2. IHC on normal human tissues found that ALPPL2 is expressed only on placental trophoblasts, but not on any other normal tissues. This significant tissue specificity and broad tumor type coverage suggest that ALPPL2 could be an excellent cell surface target for therapeutic development against mesothelioma. To evaluate therapeutic potential of ALPPL2 targeting, an ALPPL2-targeted antibody–drug conjugate was developed and demonstrated potent and specific tumor killing in vitro and in vivo against both epithelioid and sarcomatoid mesothelioma. Thus, ALPPL2 belongs to a rare class of cell surface antigens classified as truly tumor specific and is well suited for therapy development against ALPPL2-expressing tumors. Significance: These findings identify ALPP2 as a true tumor-specific cell surface antigen whose tissue specificity enables the development of novel therapies.Keywords
All Related Versions
Funding Information
- NIH (R01 CA129491, CA118919, CA171315)
This publication has 37 references indexed in Scilit:
- Immunolocalization of nestin, mesothelin and epithelial membrane antigen (EMA) in developing and adult serous membranes and mesotheliomasActa Histochemica, 2012
- Rapid generation of fully human monoclonal antibodies specific to a vaccinating antigenNature Protocols, 2009
- Identification of MCAM/CD146 as the Target Antigen of a Human Monoclonal Antibody that Recognizes Both Epithelioid and Sarcomatoid Types of MesotheliomaCancer Research, 2009
- Malignant mesothelioma 2008Current Opinion in Pulmonary Medicine, 2008
- Targeted drug delivery to mesothelioma cells using functionally selected internalizing human single-chain antibodiesMolecular Cancer Therapeutics, 2008
- MESOMARK®in vitrodiagnostic test for mesotheliomaExpert Opinion on Medical Diagnostics, 2007
- Identification of Clinically Significant Tumor Antigens by Selecting Phage Antibody Library on Tumor Cells in Situ Using Laser Capture MicrodissectionMolecular & Cellular Proteomics, 2006
- Enhanced Activity of Monomethylauristatin F through Monoclonal Antibody Delivery: Effects of Linker Technology on Efficacy and ToxicityBioconjugate Chemistry, 2005
- Saporin and ricin A chain follow different intracellular routes to enter the cytosol of intoxicated cellsThe FEBS Journal, 2005
- Structural and functional analysis of human germ cell alkaline phosphatase by site-specific mutagenesisBiochemistry, 1992